



To: Medical Staff, House Staff, Patient Care Centers, and Outpatient Clinics

From: Kathleen G. Beavis, MD, Medical Director, Clinical Microbiology and Immunology Laboratory

Karen Ironkwe, Manager, Clinical Microbiology and Immunology Laboratory

Natasha N. Pettit, PharmD, Pharmacy Director, Antimicrobial Stewardship Program

Date: 6/5/2024

Subject: BioFire Blood Culture Identification Panel (BCID2) Implementation

Effective Date: 6/5/2024

Laboratory Section: Clinical Microbiology and Immunology

Summary: Effective today, the Clinical Microbiology and Immunology Laboratory is performing the BioFire Rapid Blood Culture Identification Panel (BCID2). BCID2 is a PCR-based assay that identifies over 25 different bacteria and yeast, as well as 10 genes commonly associated with antimicrobial resistance. This rapid identification will permit adjustment of broad-based empiric therapy to targeted therapy in a more timely manner.

In partnership with our colleagues in Antimicrobial Stewardship, a [guideline](#) was prepared to assist in interpretation of the findings. Targeted therapy will improve patient outcomes while decreasing hospitalization costs and antimicrobial resistance.

The Microbiology Laboratory will perform the BCID2 panel on positive blood cultures. Results will typically be available in EPIC within 2-3 hours after the Gram stain result. BCID2 will not be repeated on the same patient unless there is a new encounter or different Gram stain results.

Verification of the FDA - approved BCID2 panel was performed and approved by the UCM Clinical Microbiology and Immunology Laboratory.

Questions: If there are any questions regarding the change, test requirements, and interpretation please contact: Karen Ironkwe Karen.Ironkwe@uchicagomedicine.org and Nedra Love Nedra.Love@uchicagomedicine.org in the Clinical Microbiology and Immunology Laboratory, or Natasha N. Pettit, PharmD Natasha.Pettit@uchicagomedicine.org from Antimicrobial Stewardship.